Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inotuzumab ozogamicin in relapsed/refractory CD22+ ALL in Chinese patients
NCT05687032Phase 4Completed
- Sponsor
- Pfizer
- Start
- Feb 2023
- Primary completion
- Aug 2024
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of inotuzumab ozogamicin in acute lymphoblastic leukemia (ALL), sponsored by Pfizer. Started Feb 2023; status: completed.
02
Drugs
inotuzumab ozogamicin
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT05687032.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05687032.